Richmond Behavioral Associates
Richmond Behavioral Associates
Staten Island, New York, United States15 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder | Cannabis Withdrawal | Recruiting | Phase 3 | 2026-09-28 | NCT07644052 | |
| Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients | Irritability Associated With Autism Spectrum Disorder | Recruiting | Phase 3 | 2026-09-25 | NCT06706674 | |
| Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder | anxiety disorder, generalized anxiety disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-09-25 | NCT06701903 | |
| Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder | Bipolar and Related Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, autism spectrum disorder, bipolar disorder, mood disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-25 | NCT06229210 | |
| A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder | Mania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder | Recruiting | Phase 3 | 2026-09-22 | NCT06951698 | |
| A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3) | Mania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder | Recruiting | Phase 3 | 2026-09-14 | NCT06929273 | |
| An Open-Label Study of Azetukalner in Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Enrolling by invitation | Phase 3 | 2026-09-03 | NCT06922110 | |
| A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) | Bipolar and Related Disorders, bipolar I disorder, bipolar II disorder, bipolar disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-09-02 | NCT07172516 | |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder | Mania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, bipolar I disorder, nervous system disorder | Active, not recruiting | Phase 2 | 2026-08-10 | NCT07046494 | |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-08-03 | NCT06775379 | |
| ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) | autism, autism spectrum disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder | Active, not recruiting | Phase 2 | 2026-07-20 | NCT05889273 | |
| A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine | Bipolar and Related Disorders, Mania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, bipolar disorder, mood disorder, nervous system disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-06-23 | NCT07140913 | |
| A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-05-18 | NCT06709014 | |
| A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-01-21 | NCT05026866 | |
| ERG Components in Schizophrenia and Bipolar Disorder Type I | Schizophrenia Spectrum and Other Psychotic Disorders, bipolar I disorder, psychiatric disorder, schizophrenia | Active, not recruiting | Not stated | 2025-08-22 | NCT03788811 |